Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KZIA
stocks logo

KZIA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.380
sliders
Low
13.00
Averages
16.50
High
20.00
Current: 13.380
sliders
Low
13.00
Averages
16.50
High
20.00
H.C. Wainwright
Sean Lee
Buy
upgrade
$2 -> $13
2025-07-10
Reason
H.C. Wainwright
Sean Lee
Price Target
$2 -> $13
2025-07-10
upgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee raised the firm's price target on Kazia Therapeutics to $13 from $2 and keeps a Buy rating on the shares following the adjusted ratio of U.S. shares to 500:1 from 100:1.
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$3
2025-02-06
Reason
Maxim Group
Jason McCarthy
Price Target
$3
2025-02-06
Initiates
Strong Buy
Reason
Maxim initiated coverage of Kazia Therapeutics with a Buy rating and $3 price target. The company's lead asset is paxalisib, a potent, oral, brain-penetrant small molecule inhibitor of PI3K and mTOR being developed as an adjuvant therapy to treat newly diagnosed unmethylated glioblastoma - GBM - multiforme, the analyst tells investors in a research note. Paxalisib has shown numerical overall survival benefits in two studies involving unmethylated GBM patients, and while the drug did not progress to the second stage after being evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment platform trial, it demonstrated consistent overall survival benefits with a prior Phase 2 study, Maxim notes, adding that Kazia is on pace to initiate a Phase 3 trial for paxalisib in the second half of this year.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kazia Therapeutics Ltd (KZIA.O) is -1498.96, compared to its 5-year average forward P/E of -79.97. For a more detailed relative valuation and DCF analysis to assess Kazia Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-79.97
Current PE
-1498.96
Overvalued PE
139.35
Undervalued PE
-299.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.52
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.00
Undervalued EV/EBITDA
-7.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
293.82
Current PS
0.00
Overvalued PS
1297.80
Undervalued PS
-710.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KZIA News & Events

Events Timeline

(ET)
2025-12-02
09:50:00
Kazia Therapeutics Resumes Trading
select
2025-12-02
09:40:00
Kazia Therapeutics Trading Halted Due to Volatility Trading Pause
select
2025-12-02
09:20:00
Kazia Therapeutics Secures $50M in Private Placement Financing
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-03Benzinga
PinnedUpdates on Kazia Therapeutics: Current Developments in Cancer Research

  • Private Placement Announcement: Kazia Therapeutics announced a private placement of approximately $50 million in shares and prefunded warrants, with net proceeds expected to be around $46.5 million to support clinical development of its lead program, paxalisib, and other corporate purposes.

  • Clinical Trial Progress: The company reported an initial immune-complete response in a patient with stage IV triple-negative breast cancer treated with paxalisib, pembrolizumab, and standard chemotherapy, showing complete resolution of previously identified lesions after three months.

  • Stock Performance and Predictions: KZIA stock is currently up 10.49% at $10.11, with analysts projecting an average 1-year price target of $20.0, indicating a potential upside of 104.12%, and no bearish recommendations from analysts.

  • Cash Runway Extension: The net proceeds from the PIPE, along with existing cash, are expected to extend Kazia's cash runway into the second half of 2028, ensuring continued support for its clinical programs.

[object Object]
Preview
8.5
12-02Newsfilter
PinnedKazia Therapeutics Secures $50 Million in PIPE Financing
  • Financing Size: Kazia Therapeutics has entered into a securities purchase agreement for approximately $50 million in PIPE financing, expected to close on December 3, 2025, enhancing the company's financial strength to support its R&D efforts.
  • Net Proceeds Expectation: The net proceeds from this financing are anticipated to be around $46.5 million after deducting related fees, which will be used to advance the clinical development of its lead program, paxalisib, thereby increasing the company's competitiveness in brain cancer treatment.
  • Cash Runway Extension: This financing is expected to extend Kazia's cash runway into the second half of 2028, ensuring sufficient funding for R&D and operations over the coming years.
  • Registration Statement Commitment: The company has committed to filing a registration statement with the SEC within 30 days post-closing to facilitate future resale of securities, enhancing investor confidence and ensuring compliance with regulatory requirements.
[object Object]
Preview
9.0
11-19Benzinga
What Caused Kazia Therapeutics' Over 51% Jump in After-Hours Trading?

  • Stock Surge: Kazia Therapeutics (KZIA) shares rose 51.74% to $8.74 after positive clinical data on metastatic triple-negative breast cancer, where a patient achieved an immune-complete response after treatment with paxalisib and pembrolizumab.

  • Clinical Findings: The company reported a significant reduction in tumor burden, with a patient showing an 86% decrease after three weeks of treatment, highlighting the rarity of complete responses in stage IV metastatic TNBC.

  • Upcoming Presentations: Kazia has two presentations accepted at the 2025 San Antonio Breast Cancer Symposium, focusing on the safety and efficacy of paxalisib in combination therapies for advanced breast cancer.

  • Nasdaq Compliance Issues: Kazia received a notice from Nasdaq regarding non-compliance with the $35 million market value requirement, and plans to appeal, which will delay any potential suspension or delisting actions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kazia Therapeutics Ltd (KZIA) stock price today?

The current price of KZIA is 13.38 USD — it has increased 0.98 % in the last trading day.

arrow icon

What is Kazia Therapeutics Ltd (KZIA)'s business?

Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

arrow icon

What is the price predicton of KZIA Stock?

Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kazia Therapeutics Ltd (KZIA)'s revenue for the last quarter?

Kazia Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Kazia Therapeutics Ltd (KZIA)'s earnings per share (EPS) for the last quarter?

Kazia Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Kazia Therapeutics Ltd (KZIA)'s fundamentals?

The market is revising No Change the revenue expectations for KZIA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 72.42%.
arrow icon

How many employees does Kazia Therapeutics Ltd (KZIA). have?

Kazia Therapeutics Ltd (KZIA) has 9 emplpoyees as of December 05 2025.

arrow icon

What is Kazia Therapeutics Ltd (KZIA) market cap?

Today KZIA has the market capitalization of 142.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free